<DOC>
	<DOC>NCT02165761</DOC>
	<brief_summary>To characterize the GORE® Hybrid Vascular Graft as compared to non-heparin bonded synthetic vascular grafts in terms of the prevalence and persistence of anti-platelet factor 4 / heparin antibodies (anti-PF4 / H antibodies).</brief_summary>
	<brief_title>Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Platelet Factor 4</mesh_term>
	<criteria>The patient is not a candidate for a native fistula. The patient requires the creation of an upper arm vascular access graft for hemodialysis secondary to a diagnosis of EndStage Renal Disease. The patient has been on hemodialysis for ≥1 month. The patient is scheduled for a different surgical procedure within 30 days post Index Procedure. The patient has a known hypercoagulable disorder or bleeding disorder. The patient has had a previous instance of Heparin Induced Thrombocytopenia Type II (HIT type II) or has known sensitivity to heparin.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>End Stage Renal Disease</keyword>
	<keyword>Vascular Graft</keyword>
</DOC>